Hello All
We've been contacted by All Wales Therapeutics and Toxicology Centre (AWTTC), who are involved in considering treatment availability in Wales. They are currently involved in the process of reviewing bevacizumab for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
We are asked to submit comments from the patient perspective, to add to the information on clinical effectiveness and cost-effectiveness which will already be submitted.
If you have any comments or experiences you would be willing to share to inform our submission please leave a comment below or email me at support@ovacome.org.uk . You don't need to be living in Wales to contribute your comments.
I won't include any names or identifiable details. Please do get in touch if you have any queries.
Best wishes
Anna
Ovacome Support Service Manager